WO2009073104A3 - Adénovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci - Google Patents

Adénovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci Download PDF

Info

Publication number
WO2009073104A3
WO2009073104A3 PCT/US2008/013066 US2008013066W WO2009073104A3 WO 2009073104 A3 WO2009073104 A3 WO 2009073104A3 US 2008013066 W US2008013066 W US 2008013066W WO 2009073104 A3 WO2009073104 A3 WO 2009073104A3
Authority
WO
WIPO (PCT)
Prior art keywords
simian
sadv
simian adenovirus
adenoviruses
adenoviruses sadv
Prior art date
Application number
PCT/US2008/013066
Other languages
English (en)
Other versions
WO2009073104A8 (fr
WO2009073104A2 (fr
Inventor
Soumitra Roy
James M Wilson
Luc H Vandenberghe
Original Assignee
Univ Pennsylvania
Soumitra Roy
James M Wilson
Luc H Vandenberghe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK08857159.1T priority Critical patent/DK2220241T3/en
Priority to JP2010535987A priority patent/JP5740158B2/ja
Application filed by Univ Pennsylvania, Soumitra Roy, James M Wilson, Luc H Vandenberghe filed Critical Univ Pennsylvania
Priority to MX2010005858A priority patent/MX2010005858A/es
Priority to CN200880118591.5A priority patent/CN101883858B/zh
Priority to KR1020157025105A priority patent/KR101662574B1/ko
Priority to CA2706258A priority patent/CA2706258C/fr
Priority to SI200831730T priority patent/SI2220241T1/sl
Priority to KR1020167026650A priority patent/KR101761691B1/ko
Priority to LTEP08857159.1T priority patent/LT2220241T/lt
Priority to AU2008331906A priority patent/AU2008331906B2/en
Priority to US12/744,441 priority patent/US8685387B2/en
Priority to MX2014000110A priority patent/MX347246B/es
Priority to ES08857159.1T priority patent/ES2607029T3/es
Priority to EP08857159.1A priority patent/EP2220241B1/fr
Priority to BRPI0819783-0A priority patent/BRPI0819783A2/pt
Publication of WO2009073104A2 publication Critical patent/WO2009073104A2/fr
Publication of WO2009073104A3 publication Critical patent/WO2009073104A3/fr
Priority to US14/178,738 priority patent/US9359618B2/en
Publication of WO2009073104A8 publication Critical patent/WO2009073104A8/fr
Priority to US15/154,368 priority patent/US20160244783A1/en
Priority to HRP20161573TT priority patent/HRP20161573T1/hr
Priority to CY20161101281T priority patent/CY1118351T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un vecteur recombinant qui comprend des séquences adénovirales simiennes SAdV-39, -25.2, -26, - 30, -37, et -38 et un gène hétérologue sous le contrôle de séquences régulatrices. Elle concerne également une lignée cellulaire exprimant un ou plusieurs gènes adénoviraux simiens SAdV-39, -25.2, -26, -30, -37, et -383. Elle concerne enfin, des procédés d'utilisation de ces vecteurs et de ces lignées cellulaires.
PCT/US2008/013066 2007-11-28 2008-11-24 Adénovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci WO2009073104A2 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
LTEP08857159.1T LT2220241T (lt) 2007-11-28 2008-11-24 Adenovirusas, apimantis beždžionių e adenoviruso sadv-39 kapsidės heksono baltymą, ir jo panaudojimas
AU2008331906A AU2008331906B2 (en) 2007-11-28 2008-11-24 Simian E adenovirus SAdV-39
MX2010005858A MX2010005858A (es) 2007-11-28 2008-11-24 Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.
CN200880118591.5A CN101883858B (zh) 2007-11-28 2008-11-24 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
KR1020157025105A KR101662574B1 (ko) 2007-11-28 2008-11-24 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
CA2706258A CA2706258C (fr) 2007-11-28 2008-11-24 Adenovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci
SI200831730T SI2220241T1 (sl) 2007-11-28 2008-11-24 Adenovirus, ki obsega kapsidni heksonski protein opičjega E adenovirusa SAdV-39, in njegove uporabe
KR1020167026650A KR101761691B1 (ko) 2007-11-28 2008-11-24 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
MX2014000110A MX347246B (es) 2007-11-28 2008-11-24 Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.
DK08857159.1T DK2220241T3 (en) 2007-11-28 2008-11-24 Adenovirus comprising a simian adenovirus E-SAdV-39-capsidhexonprotein and uses thereof
US12/744,441 US8685387B2 (en) 2007-11-28 2008-11-24 Simian E adenoviruses SAdV-39, -25.2, -26, -30, -37, and -38
JP2010535987A JP5740158B2 (ja) 2007-11-28 2008-11-24 サルＥアデノウイルスＳＡｄＶ−３９、−２５．２、−２６、−３０、−３７および−３８
ES08857159.1T ES2607029T3 (es) 2007-11-28 2008-11-24 Adenovirus que comprende una proteína hexónica de la cápside del adenovirus E de simio SAdV-39 y usos de la misma
EP08857159.1A EP2220241B1 (fr) 2007-11-28 2008-11-24 Adénovirus comprenant une protéine hexon capsidaire d'adénovirus E simien SAdV-39 et son utilisation
BRPI0819783-0A BRPI0819783A2 (pt) 2007-11-28 2008-11-24 Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos.
US14/178,738 US9359618B2 (en) 2007-11-28 2014-02-12 Simian subfamily E adenoviruses SAdV-39, -25.2, -26, -30, -37, and -38 and uses thereof
US15/154,368 US20160244783A1 (en) 2007-11-28 2016-05-13 SIMIAN SUBFAMILY E ADENOVIRUSES SAdV-39, -25.2, -26, -30, -37, AND -38 AND USES THEREOF
HRP20161573TT HRP20161573T1 (hr) 2007-11-28 2016-11-24 ADENOVIRUS KOJI SADRŽI KAPSIDNI HEKSON PROTEIN ADENOVIRUSA E MAJMUNA SAdV-39 I NJEGOVE PRIMJENE
CY20161101281T CY1118351T1 (el) 2007-11-28 2016-12-13 ΑΔΕΝΟΪΟΣ ΑΠΟΤΕΛΟΥΜΕΝΟΣ ΑΠΟ ΠΡΩΤΕΪΝΗ ΕΞΩΝΙΟΥ ΚΑΨΙΔΙΟΥ SAdV-39 ΑΔΕΝΟΪΟΥ Ε ΠΙΘΗΚΟΥ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US449907P 2007-11-28 2007-11-28
US446107P 2007-11-28 2007-11-28
US453207P 2007-11-28 2007-11-28
US454107P 2007-11-28 2007-11-28
US446407P 2007-11-28 2007-11-28
US450707P 2007-11-28 2007-11-28
US61/004,532 2007-11-28
US61/004,507 2007-11-28
US61/004,541 2007-11-28
US61/004,461 2007-11-28
US61,004,499 2007-11-28
US61,004,464 2007-11-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/744,441 A-371-Of-International US8685387B2 (en) 2007-11-28 2008-11-24 Simian E adenoviruses SAdV-39, -25.2, -26, -30, -37, and -38
US14/178,738 Division US9359618B2 (en) 2007-11-28 2014-02-12 Simian subfamily E adenoviruses SAdV-39, -25.2, -26, -30, -37, and -38 and uses thereof

Publications (3)

Publication Number Publication Date
WO2009073104A2 WO2009073104A2 (fr) 2009-06-11
WO2009073104A3 true WO2009073104A3 (fr) 2009-08-20
WO2009073104A8 WO2009073104A8 (fr) 2016-03-31

Family

ID=40380705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/013066 WO2009073104A2 (fr) 2007-11-28 2008-11-24 Adénovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci

Country Status (20)

Country Link
US (3) US8685387B2 (fr)
EP (2) EP3128010A1 (fr)
JP (3) JP5740158B2 (fr)
KR (3) KR101614364B1 (fr)
CN (1) CN101883858B (fr)
AU (1) AU2008331906B2 (fr)
BR (1) BRPI0819783A2 (fr)
CA (2) CA2706258C (fr)
CY (1) CY1118351T1 (fr)
DK (1) DK2220241T3 (fr)
ES (1) ES2607029T3 (fr)
HR (1) HRP20161573T1 (fr)
HU (1) HUE032142T2 (fr)
LT (1) LT2220241T (fr)
MX (2) MX2010005858A (fr)
PL (1) PL2220241T3 (fr)
PT (1) PT2220241T (fr)
SG (1) SG10201604001XA (fr)
SI (1) SI2220241T1 (fr)
WO (1) WO2009073104A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008331906B2 (en) 2007-11-28 2014-03-06 The Trustees Of The University Of Pennsylvania Simian E adenovirus SAdV-39
EP2463362B1 (fr) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Adénovirus SAdv-31 de la sous-famille C des simiens et ses utilisations
JP5740157B2 (ja) 2007-11-28 2015-06-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルサブファミリーＢアデノウイルスＳＡｄＶ−２８、−２７、−２９、−３２、−３３および−３５ならびにそれらの用途
CA2716928C (fr) 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Adenovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
WO2010051367A1 (fr) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-43, -45, -48, -49 et –50 et leurs utilisations
WO2010085984A1 (fr) * 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
ES2898235T3 (es) 2009-02-02 2022-03-04 Glaxosmithkline Biologicals Sa Secuencias de aminoácidos y de ácidos nucleicos de adenovirus de simio, vectores que las contienen, y sus usos
EP2435559A1 (fr) 2009-05-29 2012-04-04 The Trustees Of The University Of Pennsylvania Adénovirus simien 41 et ses utilisations
WO2011057254A2 (fr) * 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccins à base de vecteur adénoviral simien
EP2498791B1 (fr) * 2009-11-09 2014-12-24 GenVec, Inc. Procédés de propagation des vecteurs d´adenovirus simiens
WO2012071318A2 (fr) * 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Adénovirus simiens de la sous-famille e a1321, a1325, a1295, a1309, a1316 et a1322 et utilisations de ceux-ci
ES2696551T3 (es) 2010-12-17 2019-01-16 Globeimmune Inc Composiciones y métodos para el tratamiento o la prevención de la infección por adenovirus-36 humano
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
US9267112B2 (en) 2011-05-10 2016-02-23 The Regents Of The University Of California Adenovirus isolated from Titi Monkeys
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045668A2 (fr) 2011-09-29 2013-04-04 Transgene Sa Composition et schéma immunothérapeutique de traitement d'une infection par le virus de l'hépatite c
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
MX358019B (es) * 2012-05-18 2018-08-02 Univ Pennsylvania Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
BR112015002004A2 (pt) * 2012-08-03 2017-07-04 Cedars Sinai Medical Center isolamento de mutantes melhoradores de tráfego de proteínas transportadoras de medicamentos
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2016057387A1 (fr) 2014-10-06 2016-04-14 The Trustees Of The University Of Pennsylvania Compositions et méthodes permettant l'isolement de cellules tumorales circulantes (ctc)
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
SG11201703281RA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN112410339A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
EP3230441A4 (fr) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions et méthodes pour la production de scaav
WO2016131945A1 (fr) 2015-02-20 2016-08-25 Transgene Sa Produit de combinaison modulateur de l'autophagie
EP3307313A1 (fr) * 2015-06-12 2018-04-18 GlaxoSmithKline Biologicals SA Polypeptides et polynucléotides d'adénovirus
US10983110B2 (en) 2015-12-02 2021-04-20 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
CA3013637A1 (fr) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Dosage a haut debit pour mesurer la cinetique de replication d'un adenovirus
CN108699566B (zh) 2016-02-23 2023-06-30 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
WO2017189964A2 (fr) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017191147A1 (fr) 2016-05-04 2017-11-09 Transgene Sa Polythérapie avec un ligand de tlr9 cpg
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
CA3024449A1 (fr) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions et methodes de traitement de la maladie de huntington
JP2019531787A (ja) 2016-08-30 2019-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
EP3532082A4 (fr) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Adénovirus synthétiques ciblant une tumeur et leurs utilisations
SG11201909868YA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
KR20200044793A (ko) 2017-08-03 2020-04-29 보이저 테라퓨틱스, 인크. Aav의 전달을 위한 조성물 및 방법
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
WO2019079242A1 (fr) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Traitement de la sclérose latérale amyotrophique (sla)
EP3703722B1 (fr) * 2017-10-31 2024-06-12 Janssen Vaccines & Prevention B.V. Adénovirus et leurs utilisations
MA50502A (fr) * 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
CA3078685A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus et utilisations associees
EP3704256A1 (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Vecteurs d'adénovirus et leurs utilisations
US12060567B2 (en) 2018-06-13 2024-08-13 Voyager Therapeutics, Inc. Engineered untranslated regions (UTR) for AAV production
JP7413629B2 (ja) 2018-07-17 2024-01-16 ヘリックスミス カンパニー， リミテッド Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療
JP2021530548A (ja) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
WO2020072849A1 (fr) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Procédés de mesure du titre et de la puissance de particules de vecteur viral
CN113166731A (zh) 2018-10-05 2021-07-23 沃雅戈治疗公司 编码aav生产蛋白的工程化核酸构建体
WO2020081490A1 (fr) 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. Vecteurs d'expression pour la production à grande échelle de raav dans le système baculovirus/sf9
WO2020160508A1 (fr) 2019-01-31 2020-08-06 Oregon Health & Science University Méthodes d'utilisation d'une évolution dirigée, dépendant d'une transcription, de capsides aav
TW202217002A (zh) 2020-07-13 2022-05-01 法商傳斯堅公司 免疫抑制之治療
EP4284335A1 (fr) 2021-02-01 2023-12-06 RegenxBio Inc. Thérapie génique de céroïdes-lipofuscinoses neuronales
WO2022218997A1 (fr) 2021-04-12 2022-10-20 Centre National De La Recherche Scientifique (Cnrs) Nouveau système de présentation de vaccin universel
WO2023213764A1 (fr) 2022-05-02 2023-11-09 Transgene Polypeptide de fusion comprenant un anti-pd-l1 sdab et un membre du tnfsf

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029334A1 (fr) * 1997-12-12 1999-06-17 Saint Louis University CtIP, UNE NOUVELLE PROTEINE INTERAGISSANT AVEC CtBP ET SES UTILISATIONS
WO2003000851A2 (fr) * 2001-06-22 2003-01-03 The Trustees Of The University Of Pennsylvania Procede de criblage rapide pour transformants bacteriens, et proteines adenovirales d'origine simienne
WO2003046124A2 (fr) * 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Sequences d'acides nucleiques et d'acides amines d'adenovirus simiens, vecteurs les contenant et procedes d'utilisation associes
WO2005001103A2 (fr) * 2003-06-20 2005-01-06 The Trustees Of The University Of Pennsylvania Procede pour produire des adenovirus chimeriques et utilisations de ces derniers
WO2005071093A2 (fr) * 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Porteurs de vaccin adenoviral de chimpanze

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1364343A1 (ru) 1984-07-13 1988-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Способ получени человеческого лейкоцитарного интерферона альфа-2
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4732683A (en) 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
JPH10507758A (ja) 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
AU704391B2 (en) 1994-10-28 1999-04-22 Trustees Of The University Of Pennsylvania, The Improved adenovirus and methods of use thereof
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
AU722624B2 (en) 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
CA2303768C (fr) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Procedes et produits genetiques vectoriels utiles pour obtenir un virus adeno-associe (aav)
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
WO1999047691A1 (fr) 1998-03-20 1999-09-23 Trustees Of The University Of Pennsylvania Compositions et methodes de production de virus adeno-associes recombines sans auxiliaire
WO2000011140A1 (fr) 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Techniques permettant d'augmenter l'immunite des muqueuses par l'intermediaire d'un premier vaccin systemique et d'un rappel mucosal
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
EA200200724A1 (ru) 2000-01-31 2003-02-27 Смитклайн Бичем Байолоджикалз С.А. Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US20080004236A1 (en) 2004-02-06 2008-01-03 Comper Wayne D High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections
PT1802336E (pt) 2004-10-14 2011-11-15 Glaxosmithkline Biolog Sa Vacinas de dose inicial/reforço para a malária
WO2006085092A2 (fr) 2005-02-12 2006-08-17 Viranative Ab Procede et utilisations d'anticorps dans la purification d'interferon
KR101451620B1 (ko) * 2005-05-12 2014-10-21 글락소 그룹 리미티드 백신 조성물
RS51250B (sr) 2006-04-28 2010-12-31 The Trustees Of The University Of Pennsylvania Modifikovani hekson protein adenovirusa i njegova upotreba
JP5740157B2 (ja) 2007-11-28 2015-06-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルサブファミリーＢアデノウイルスＳＡｄＶ−２８、−２７、−２９、−３２、−３３および−３５ならびにそれらの用途
EP2463362B1 (fr) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Adénovirus SAdv-31 de la sous-famille C des simiens et ses utilisations
AU2008331906B2 (en) 2007-11-28 2014-03-06 The Trustees Of The University Of Pennsylvania Simian E adenovirus SAdV-39
CA2716928C (fr) 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Adenovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
EP2777185B1 (fr) 2011-10-13 2016-08-24 Telefonaktiebolaget LM Ericsson (publ) Procédé et noeud ayant trait à l'estimation de canal

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029334A1 (fr) * 1997-12-12 1999-06-17 Saint Louis University CtIP, UNE NOUVELLE PROTEINE INTERAGISSANT AVEC CtBP ET SES UTILISATIONS
WO2003000851A2 (fr) * 2001-06-22 2003-01-03 The Trustees Of The University Of Pennsylvania Procede de criblage rapide pour transformants bacteriens, et proteines adenovirales d'origine simienne
WO2003046124A2 (fr) * 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Sequences d'acides nucleiques et d'acides amines d'adenovirus simiens, vecteurs les contenant et procedes d'utilisation associes
US20050069866A1 (en) * 2001-11-21 2005-03-31 Wilson James M. Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2005001103A2 (fr) * 2003-06-20 2005-01-06 The Trustees Of The University Of Pennsylvania Procede pour produire des adenovirus chimeriques et utilisations de ces derniers
WO2005071093A2 (fr) * 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Porteurs de vaccin adenoviral de chimpanze

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FARINA S F ET AL: "Replication-defective vector based on a Chimpanzee adenovirus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 23, 1 December 2001 (2001-12-01), pages 11603 - 11613, XP002957497, ISSN: 0022-538X *
ROY ET AL: "Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 25, no. 39-40, 15 September 2007 (2007-09-15), pages 6845 - 6851, XP022250370, ISSN: 0264-410X *
ROY S ET AL: "Complete nucleotide sequences and genome organization of four chimpanzee adenoviruses", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 324, no. 2, 1 July 2004 (2004-07-01), pages 361 - 372, XP004519188, ISSN: 0042-6822 *
ROY SOUMITRA ET AL: "Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 15, no. 5, 1 May 2004 (2004-05-01), pages 519 - 530, XP002301507, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
ES2607029T3 (es) 2017-03-28
DK2220241T3 (en) 2017-01-09
PL2220241T3 (pl) 2017-06-30
US20160244783A1 (en) 2016-08-25
CA2964396A1 (fr) 2009-06-11
KR20160118370A (ko) 2016-10-11
CN101883858B (zh) 2015-07-22
SG10201604001XA (en) 2016-07-28
KR20100109915A (ko) 2010-10-11
CY1118351T1 (el) 2017-06-28
JP2016195595A (ja) 2016-11-24
SI2220241T1 (sl) 2017-02-28
KR101614364B1 (ko) 2016-04-22
LT2220241T (lt) 2016-12-12
KR20150108945A (ko) 2015-09-30
WO2009073104A8 (fr) 2016-03-31
JP5740158B2 (ja) 2015-06-24
HRP20161573T1 (hr) 2017-02-10
CA2706258C (fr) 2017-06-06
US20100247490A1 (en) 2010-09-30
HUE032142T2 (en) 2017-08-28
US9359618B2 (en) 2016-06-07
PT2220241T (pt) 2016-12-26
KR101761691B1 (ko) 2017-07-26
AU2008331906A1 (en) 2009-06-11
WO2009073104A2 (fr) 2009-06-11
US8685387B2 (en) 2014-04-01
JP6224769B2 (ja) 2017-11-01
EP3128010A1 (fr) 2017-02-08
JP2015083006A (ja) 2015-04-30
EP2220241A2 (fr) 2010-08-25
CA2706258A1 (fr) 2009-06-11
EP2220241B1 (fr) 2016-09-14
MX347246B (es) 2017-04-19
US20140155476A1 (en) 2014-06-05
AU2008331906B2 (en) 2014-03-06
CN101883858A (zh) 2010-11-10
BRPI0819783A2 (pt) 2015-06-23
JP2011522513A (ja) 2011-08-04
KR101662574B1 (ko) 2016-10-05
MX2010005858A (es) 2010-06-11

Similar Documents

Publication Publication Date Title
WO2009073104A3 (fr) Adénovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci
WO2009136977A3 (fr) Adénovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
WO2009105084A8 (fr) Adénovirus c de la sous-famille simiesque sadv-40, -31, et -34 et leurs utilisations
WO2012071318A3 (fr) Adénovirus simiens de la sous-famille e a1321, a1325, a1295, a1309, a1316 et a1322 et utilisations de ceux-ci
WO2009073103A3 (fr) Adénovirus simiens sadv-28,27,-29,-32,-33, et -35 de la sous-famille b et utilisations de ceux-ci
WO2013173702A3 (fr) Adénovirus simiens de la sous-famille e a1302, a1320, a1331 et a1337 et leurs utilisations
WO2003046124A3 (fr) Sequences d'acides nucleiques et d'acides amines d'adenovirus simiens, vecteurs les contenant et procedes d'utilisation associes
WO2009042971A3 (fr) Régions non traduites 5' (5'utr) synthétiques, vecteurs d'expression, et procédés pour augmenter l'expression transgénique
WO2008122811A3 (fr) Nouveaux vecteurs adénoviraux
WO2008010864A3 (fr) Protéine hexon d'adénovirus modifiée et ses utilisations
WO2006026331A3 (fr) Vecteurs adenoviraux modifies a fibres ameliorant la trnsduction des cellules tumorales
EP1771570A4 (fr) Addition de transgènes dans des vecteurs adénoviraux
WO2008094512A3 (fr) Système provenant d'un vecteur d'expression viral utilisé pour exprimer des gènes chez des végétaux
UA106733C2 (uk) Вектор експресії
WO2007134325A3 (fr) Procédés et compositions pour la production de protéines à l'aide de vecteurs adénoviraux
WO2006110240A3 (fr) Transfert de genes au moyen d'adenovirus presentant des proteines fibres modifiees
WO2012083297A3 (fr) Vecteurs adénoviraux avec régions d'hexon modifiées
WO2008095027A3 (fr) Vecteur adenoviral comprenant une thymidine kinase de virus herpes simplex virus type 1 et un transgene pour augmenter l'expression du transgene
NZ597773A (en) Raccoon poxvirus expressing rabies glycoproteins
WO2006008468A3 (fr) Vecteur adenoviral et methodologie de manipulation du genome adenoviral
WO2005010149A3 (fr) Vecteurs adenoviraux du sous-groupe b pour le traitement de maladies
SG169325A1 (en) Promoters for expression in modified vaccinia virus ankara
WO2011153344A3 (fr) Mise au point de phénotypes microbiens complexes à transcription améliorée
WO2008107462A3 (fr) Plasmide contenant une séquence codant pour un domaine disintégrine de la métargidine (rdd)
EP2085475A4 (fr) Procede de production de souche cellulaire pouvant exprimer un gene induit par la tetracycline ou de souche cellulaire presentant une inactivation conditionnelle de genes, et utilisation des souches cellulaires

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880118591.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857159

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2706258

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008331906

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12744441

Country of ref document: US

Ref document number: 3663/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010535987

Country of ref document: JP

Ref document number: MX/A/2010/005858

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008331906

Country of ref document: AU

Date of ref document: 20081124

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107014132

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2008857159

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008857159

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0819783

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100527